176 related articles for article (PubMed ID: 37461649)
1. PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis.
Napoletani G; Soldan SS; Kannan T; Preston-Alp S; Vogel P; Maestri D; Caruso LB; Kossenkov A; Sobotka A; Lieberman PM; Tempera I
bioRxiv; 2023 Jul; ():. PubMed ID: 37461649
[TBL] [Abstract][Full Text] [Related]
2. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
3. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
4. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
5. The Epstein-Barr Virus Regulome in Lymphoblastoid Cells.
Jiang S; Zhou H; Liang J; Gerdt C; Wang C; Ke L; Schmidt SCS; Narita Y; Ma Y; Wang S; Colson T; Gewurz B; Li G; Kieff E; Zhao B
Cell Host Microbe; 2017 Oct; 22(4):561-573.e4. PubMed ID: 29024646
[TBL] [Abstract][Full Text] [Related]
6. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
Lupey-Green LN; Caruso LB; Madzo J; Martin KA; Tan Y; Hulse M; Tempera I
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976663
[TBL] [Abstract][Full Text] [Related]
7. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Martin KA; Lupey LN; Tempera I
J Virol; 2016 Oct; 90(19):8520-30. PubMed ID: 27440880
[TBL] [Abstract][Full Text] [Related]
9. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW
PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972
[TBL] [Abstract][Full Text] [Related]
10. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
11. Coordinate Regulation of TET2 and EBNA2 Controls the DNA Methylation State of Latent Epstein-Barr Virus.
Lu F; Wiedmer A; Martin KA; Wickramasinghe PJMS; Kossenkov AV; Lieberman PM
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794029
[TBL] [Abstract][Full Text] [Related]
12. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
13. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
14. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
15. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.
Chau CM; Zhang XY; McMahon SB; Lieberman PM
J Virol; 2006 Jun; 80(12):5723-32. PubMed ID: 16731911
[TBL] [Abstract][Full Text] [Related]
17. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
18. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
